Neutral
●
PRNewsWire
●
5 months ago
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M ® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing part...